Vigil Neuroscience's lead clinical candidate, iluzanebart, has failed in a mid-stage study in a rare and fatal neurodegenerative disease. Vigil on Wednesday said it is ending a Phase 2 study of ...

Our virtual Vigil activist today was Munashe Madziyauswa. He carried a placard expressing his dissatisfaction with ZANU PF, Zimbabwe’s ruling regime. Photos: https ...

Page 4 by Murewa Ayodele and Luciano Vecchio begins with several mutants entering the Hellfire Vigil through Manifold’s gateways. Next, Storm gives what can only be described as a moving ...

Former Aurora Chief Community Services Officer Viviana Ramirez, who was one of many in upper city management who recently left their positions alongside former Mayor Richard Irvin, looks back on ...

Carroll County’s 10th Annual Drug Overdose and Prevention Vigil at St. John’s Portico Thursday in Westminster. Families, friends, and community members gathered in remembrance, support ...

BRYA I’LL GIVE YOU THAT IN A FEW MINUTES. ALL RIGHT, BRIAN, THANK YOU. TONIGHT, A VIGIL HONORS THE LIFE OF A FOUR YEAR BOY. RJ O’KEEFE WAS REPORTED MISSING LAST FRIDAY NIGHT. RESCUERS FOUND ...

SANOFI will acquire Vigil Neuroscience, a clinical-stage biotech company in a $470-million deal, the companies said on Thursday, as the French drugmaker seeks to boost its neurological pipeline ...

Vigil Neuroscience (VIGL) and Sanofi (SNY) announced that it has entered into a definitive merger agreement pursuant to which Sanofi will acquire Vigil for an upfront payment of $8.00 per share of ...

Vigil Neuroscience shares more than tripled Thursday after the company reached a deal to be acquired by Sanofi. French pharmaceutical giant Sanofi agreed to pay $8.00 per share in cash at closing ...

Sanofi is expanding its neuroscience drug pipeline through the $470 million acquisition of Vigil Neuroscience, a clinical-stage biotech with a drug that could introduce a new way of treating ...

Vigil Neuroscience, Inc. (NASDAQ:VIGL) on Wednesday disclosed that it entered a deal to be acquired by Sanofi (NASDAQ:SNY) for an equity value of approximately $470 million (on a fully diluted basis).

Sanofi to acquire Vigil Neuroscience for up to $600M, including a $2/share CVR tied to VG-3927 milestones. VG-3927, a once-daily oral TREM2 agonist for Alzheimer’s, to enter Phase 2; VGL101 ...